MedRx Co., Ltd announced that it will issue 76,700 stock acquisition rights at an issue price of ¥16 per stock acquisition right for an aggregate gross proceeds of ¥1,227,200 on March 8, 2023. The transaction will include participation from returning investor, Evo Fund managed by Evolution Capital Management, LLC. The transaction has been approved by the board of directors of the company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
119 JPY | +4.39% | +4.39% | -21.19% |
1st Jan change | Capi. | |
---|---|---|
-21.19% | 30.23M | |
+6.97% | 71.94B | |
-10.86% | 5.13B | |
+46.43% | 4.66B | |
+5.38% | 3.97B | |
-16.20% | 2.55B | |
+21.10% | 2.41B | |
-26.20% | 2.36B | |
+19.92% | 2.21B | |
+8.15% | 1.71B |
- Stock Market
- Equities
- 4586 Stock
- News MedRx Co., Ltd
- MedRx Co., Ltd announced that it expects to receive ¥1.2272 million in funding from Evolution Capital Management, LLC